Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

If you want to be a millionaire more quickly, you can always invest more along the way.

Want to Get to $1 Million by Retirement? Here's How Much You Should Invest Today.

Johnson & Johnson (NYSE:JNJ) was rebuffed by the US Supreme Court Tuesday over a US$302 million judgment in a lawsuit brought by the state of California that accused the company of deliberately hiding the risk of pelvic mesh.  The court refused to hear the case, following the judgment reached in San Diego Superior Court from the 2016 suit.

Johnson & Johnson challenge to US$302mln pelvic mesh settlement denied by US Supreme Court

American States Water

Northwest Natural Gas

The power of reinvesting in dividend-paying stocks becomes obvious with these three Dividend Kings.

3 More Stocks Raising Their Dividends for Over 60 Years

Home Depot

Microsoft

These 3 dividend stocks pay safe and growing dividends. All 3 companies are among the leaders in their respective sectors.

3 Foundational Dividend Stocks To Build A Portfolio Around

Johnson & Johnson (NYSE: JNJ) recently filed a shelf registration with the SEC, suggesting it is preparing for the future. The filing is for debt securities, not shares, to be sold on an ongoing basis at a future date that could be as soon as the filing was received.

Johnson & Johnson: Taking The Bull By The Horns?

Coca-Cola

PepsiCo

Procter & Gamble

Bridgewater Associates, the hedge fund founded by Ray Dalio (Trades, Portfolio), disclosed in a regulatory portfolio update filing that its top five trades during the fourth quarter of 2022 included a new position in JPMorgan Chase & Co. ( JPM , Financial) and reductions to its holdings of four consumer defensive stocks: Proctor & Gamble Co. ( PG , Financial), Johnson & Johnson ( JNJ , Financial), Coca-Cola Co. ( KO , Financial) and PepsiCo Inc. ( PEP , Financial).

Ray Dalio's Bridgewater Slims 4 Consumer Defensive Holdings

The stock market bloodbath of 2022 has left investors wondering whether they should choose safety over aggressive growth. While many investors are still sitting out and waiting for the market to recover, smart investors know that this is the time to bag solid, long-term stocks at a discount.

The 3 Best Dividend Stocks for Beginner Investors

At the end of 2023, Johnson & Johnson will be spinning off its Consumer Health segment. Consumer Health has been the backbone of the company, but the Pharmaceutical and MedTech segments have provided the growth.

Will Johnson & Johnson Remain A Top Dividend Aristocrat Stock Going Forward?

Apple

Johnson & Johnson and Apple both have the economic moats and powerful brands that Buffett craves.

2 Warren Buffett Stocks to Buy Hand Over Fist and Hold for 30 Years or More

Alvotech SA

Amgen

Bristol-Myers

Coherus BioSciences

Cigna

CVS Health

Fresenius Medical Care

GlaxoSmithKline

Merck

Novo Nordisk

Novartis

Organon & Co

Pfizer

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Teva Pharmaceutical

Viatris

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

Broadcom

Best Buy

Caterpillar

Comcast

CubeSmart

Enterprise Products Partners

Extra Space Storage

Corning

Lowe's

ManpowerGroup

Medtronic

Trinity Industries

T. Rowe Price Group

Unum

Whirlpool

Finding companies with a high initial yield and rapid dividend growth is difficult. I present my criteria for finding such companies. At present, there are 16 companies meeting my initial screening requirements. Using additional metrics, these are reduced to five.

5 Stocks In The Dividend Growth Sweet Spot

Johnson & Johnson (NYSE:JNJ ) SVB Securities Global Biopharma Conference February 15, 2023 1:00 PM ET Company Participants Biljana Naumovic - Worldwide President, Global Oncology Peter Lebowitz - Global Therapeutic Head, Oncology R&D Conference Call Participants David Risinger - SVB Securities David Risinger Great. Good afternoon, everyone, and thank you for joining us for this next session with J&J.

Johnson & Johnson (JNJ) Presents at SVB Securities Global Biopharma Conference (Transcript)

Teladoc

Tilray Brands

Choose companies with strong fundamentals that can withstand storms and continue to thrive.

3 Resilient Stocks to Help Solidify Your Portfolio in 2023

Kroger

These stocks are low-risk investments with dividends yielding more than 2%.

Worried About 2023? Park Your Money in These 2 Low-Volatility Dividend Stocks

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors. “I am excited to welcome Dr. Paula Johnson to Johnson & Johnson's Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson.

Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14th, at the Loews Miami Beach Hotel, Miami Beach, Florida. Aldo Denti, Company Group Chairman DePuy Synthes and Peter Menziuso, Company Group Chairman, Vision will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).

Johnson & Johnson to Participate in the Barclays Global HealthCare Conference

The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead.

Better Buy: Johnson & Johnson or AbbVie?

News for Johnson & Johnson Stock (JNJ)